Article
IL-12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and…
medRxiv · 2022 · Huey Yee Teo
Key facts
| Title | IL-12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment |
|---|---|
| First author | Huey Yee Teo |
| Journal | medRxiv |
| Published | Aug 13, 2022 |
| DOI | 10.1101/2022.08.11.503563 |
| Devices mentioned | K103302 |
| Product codes mentioned | KIT, MVU, NDS, NJT, OOI |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1